Kirsten Fischer Selected Research

Kirsten Fischer Research Topics

Disease

66	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/2024 - 10/2009
13	Residual Neoplasm 05/2023 - 03/2017
11	Neoplasms (Cancer) 05/2022 - 05/2011
8	Infections 05/2024 - 03/2014
8	Disease Progression 05/2023 - 01/2015
7	Neutropenia 01/2022 - 03/2014
2	Lymphoma (Lymphomas) 12/2023 - 06/2016
2	Tumor Lysis Syndrome 05/2022 - 12/2020
2	Atrial Fibrillation 01/2022 - 01/2017
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2023
1	T-Cell Leukemia (Leukemia, T Cell) 01/2023
1	B-Cell Lymphoma (Lymphoma, B Cell) 02/2022
1	Myocardial Infarction 01/2022
1	Hemorrhage 01/2022
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Leukemia 01/2022
1	Exanthema (Rash) 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021
1	Genomic Instability 01/2021
1	Glioblastoma (Glioblastoma Multiforme) 01/2021
1	Leukocytosis (Pleocytosis) 01/2021
1	Multiple Myeloma 01/2021
1	Lymphoid Leukemia 12/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020
1	Obesity 01/2020
1	Septic Shock (Toxic Shock Syndrome) 01/2020
1	COVID-19 01/2020
1	Trisomy (Trisomies) 01/2020
1	Sepsis (Septicemia) 01/2020
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2019
1	Leukoencephalopathies 10/2017
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 10/2017
1	Mucositis 06/2016
1	Carcinogenesis 10/2015
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2011
1	Pathologic Complete Response 02/2011
1	Body Weight (Weight, Body) 10/2009

Drug/Important Bio-Agent (IBA)

22	Rituximab (Mabthera)FDA Link 05/2024 - 09/2011
21	obinutuzumabIBA 04/2024 - 03/2014
18	venetoclaxIBA 10/2023 - 11/2017
14	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2024 - 08/2013
14	fludarabineIBA 05/2024 - 10/2009
12	ibrutinibIBA 05/2023 - 01/2015
9	Bendamustine Hydrochloride FDA Link 04/2024 - 09/2011
7	Chlorambucil (Leukeran)FDA Link 10/2023 - 10/2009
4	idelalisibIBA 04/2024 - 03/2018
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 05/2011
3	AntibodiesIBA 05/2023 - 12/2020
3	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 05/2015
3	Lenalidomide (CC 5013)FDA Link 01/2021 - 09/2016
2	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2022
2	tirabrutinibIBA 06/2022 - 04/2022
2	Immunoglobulins (Immunoglobulin)IBA 11/2021 - 11/2020
2	ofatumumab FDA Link 01/2021 - 03/2018
2	Thymidine KinaseIBA 01/2020 - 01/2018
1	Drug CombinationsIBA 05/2024
1	serum P-component (CIt)IBA 01/2023
1	Lysine (L-Lysine)FDA Link 01/2023
1	Histone DemethylasesIBA 01/2023
1	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amineIBA 04/2022
1	Vincristine (Oncovin)FDA LinkGeneric 02/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2022
1	Prednisone (Sone)FDA LinkGeneric 02/2022
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2022
1	AnticoagulantsIBA 01/2022
1	Cytochrome P-450 CYP3AIBA 01/2022
1	acalabrutinibIBA 01/2021
1	hydrogen sulfite (bisulfite)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 12/2020
1	pipoxolan (BR 18)IBA 02/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	Genetic Markers (Genetic Marker)IBA 10/2017
1	Alemtuzumab (Campath)FDA Link 03/2017
1	Dihydrotachysterol (AT 10)IBA 03/2017
1	Cisplatin (Platino)FDA LinkGeneric 06/2016
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2016
1	Oxygen (Dioxygen)IBA 06/2016
1	purineIBA 06/2015
1	Tyrosine Kinase InhibitorsIBA 05/2015
1	HLA-DR Antigens (HLA-DR)IBA 05/2011

Therapy/Procedure

19	Therapeutics 04/2024 - 10/2009
6	Drug Therapy (Chemotherapy) 12/2023 - 02/2011
2	Aftercare (After-Treatment) 01/2018 - 01/2016
1	Hematopoietic Stem Cell Transplantation 01/2019
1	Duration of Therapy 03/2018